Tocilizumab for GVHD – pro
Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.Recently it found a use in COVID-19. Both positive and negative studies have been published; However, more recent studies are suggesting a significant benefit for GVHD.
Glen A. Kennedy, Siok-Keen Tey, Luke Buizen, Antiopi Varelias, Kate H. Gartlan, Cameron Curley, Stuart D. Olver, Karshing Chang, Jason P. Butler, Ashish Misra, Elango Subramoniapillai, A. James Morton, Simon Durrant, Andrea S. Henden, John Moore, David Ritchie, David Gottlieb, Julian Cooney, Sanjoy K. Paul, Geoffrey R. Hill
, A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis. Blood (2021) 137 (14): 1970–1979.
Filiz YucebayDepartment et al, Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience. Leukemia & Lymphoma
Volume 60, 2019 – Issue 9
Saurabh Chhabraet al, Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. https://haematologica.org/article/view/haematol.2022.281309, 2023
Gergis, U., & van Besien, K. (2019). Tocilizumab, in search for a role in acute GVHD. Leukemia & Lymphoma, 60(9), 2101–2103. https://doi.org/10.1080/10428194.2019.1613545